Eplontersen
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications
Eplontersen for Transthyretin Amyloid Cardiomyopathy.
Journal: The New England journal of medicine
Published: August 28, 2026
Guidelines for the management of hereditary ATTR amyloidosis 2026.
Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
Published: July 09, 2026
Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.
Journal: Journal of clinical pharmacology
Published: June 22, 2026
Impact of Baseline Polyneuropathy Severity on Eplontersen Efficacy in the NEURO-TTRansform Clinical Trial.
Journal: Journal of the peripheral nervous system : JPNS
Published: June 05, 2026
Disease modifying treatment of hereditary transthyretin amyloidosis with polyneuropathy in Germany - expert consensus of the German society of amyloid diseases (DGAK) and the German neurological society (DGN).
Journal: Neurological research and practice
Published: May 27, 2026
Disease-Modifying Therapies for Hereditary Transthyretin Amyloidosis with Polyneuropathy: Current Status and Future Perspectives.
Journal: Neurology and therapy
Published: May 23, 2026
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy.
Journal: Circulation. Heart failure
Published: May 09, 2026
Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies.
Journal: Journal of clinical medicine research
Published: April 28, 2026
Gene silencing versus protein stabilization in transthyretin amyloid cardiomyopathy: contextualizing the HELIOS-B results and the road to precision agent selection.
Journal: Annals of medicine and surgery (2012)
Published: April 20, 2026
Oligonucleotides: Evolution of Carcinogenicity and Risk Assessment Strategy.
Journal: Toxicologic pathology
Published: March 31, 2026
Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen.
Journal: European journal of heart failure
Published: March 09, 2026
Last Updated: 09/26/2026